Arcus Biosciences

Arcus Biosciences Overview

Founded 2015
Founded
Status Public
Employees 139
Employees
Stock Symbol RCUS
Stock Symbol
Share Price $31.35 (As of Friday Closing)

Arcus Biosciences General Information

Description

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company which focuses on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. The company focuses on an ATP-adenosine pathway which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. The pipeline products of the company include dual and selective A2R antagonists, small-molecule and antibody programs which target solid tumors. The company operates through the single segment being the business of developing and commercializing immunotherapies.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NYS
Primary Office
  • 3928 Point Eden Way
  • Hayward, CA 94545
  • United States
+1 (510) 000-0000

Arcus Biosciences Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Arcus Biosciences Stock Performance

(As of Tuesday closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$31.35 $28.21 $6.30 - $37.41 $1.44B 46M 704K -$2.16

Arcus Biosciences Financials Summary

In Thousands,
USD
TTM 31-Mar-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 449,852 272,187 220,930
Revenue 15,000 15,000 8,353 1,413
EBITDA (95,638) (86,333) (50,852) (51,245)
Net Income (94,793) (84,710) (49,594) (53,082)
Total Assets 176,144 203,110 274,925 190,486
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Arcus Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Arcus Biosciences‘s full profile, request access.

Request a free trial

Arcus Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Arcus Biosciences‘s full profile, request access.

Request a free trial

Arcus Biosciences Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
RAPT Therapeutics Formerly VC-backed South San Francisco, CA 00 00000 00000000 00000
000000 00000000000 Formerly VC-backed Burlingame, CA 00 00000 00000000 00000
00000000 000000000 Formerly VC-backed Newtown, PA 00 00000 00000000 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
00000 Formerly PE-Backed Paris, France 00 00000 00000000000 00000

Arcus Biosciences Executive Team (16)

Name Title Board Seat Contact Info
Eric Hoefer Chief Commercial Officer
Nigel Walker Ph.D Vice President
Yvonne Gehring Vice President, Human Resources & Operations
William Grossman MD Chief Medical Officer
Terry Rosen Ph.D Chief Executive Officer & Chairman

9 Former Executives

Arcus Biosciences Board Members (9)

To view Arcus Biosciences‘s full board member team, request access >>
Name Representing Role Since
David Beier JD Self Board Member 000 0000
Jennifer Jarrett Arcus Biosciences Board Member 000 0000
Juan Jaen Ph.D Self Founder & Board Member 000 0000
Kathryn Falberg Self Board Member 000 0000
Kristen Hege MD Self Board Member 000 0000

Arcus Biosciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Arcus Biosciences‘s full profile, request access.

Request a free trial